High flow nasal cannula oxygen and non-invasive mechanical ventilation in management of COVID-19 patients with acute respiratory failure: a retrospective observational study
| العنوان: | High flow nasal cannula oxygen and non-invasive mechanical ventilation in management of COVID-19 patients with acute respiratory failure: a retrospective observational study |
|---|---|
| المؤلفون: | Amr Shoukri |
| المصدر: | The Egyptian Journal of Bronchology The Egyptian Journal of Bronchology, Vol 15, Iss 1, Pp 1-7 (2021) |
| بيانات النشر: | Springer Berlin Heidelberg, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_treatment, medicine.disease_cause, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Medicine, Intensive care unit, High flow nasal cannula oxygen, lcsh:RC705-779, Mechanical ventilation, business.industry, Mortality rate, Research, lcsh:Medical emergencies. Critical care. Intensive care. First aid, COVID-19, 030208 emergency & critical care medicine, Retrospective cohort study, lcsh:Diseases of the respiratory system, lcsh:RC86-88.9, 030228 respiratory system, Respiratory failure, Anesthesia, Breathing, Non-invasive ventilation, Arterial blood, business, Nasal cannula |
| الوصف: | Background High flow nasal cannula oxygen (HFNCO) is a relatively new technique used to deliver oxygen in respiratory failure patients. This retrospective study is aiming to assess the role and benefits of using HFNCO compared to non-invasive ventilation (NIV) in management of patients with acute hypoxemic respiratory failure associated with coronavirus disease 2019 (COVID-19). Results A retrospective analysis of the files of 63 patients with COVID-19 and acute hypoxemic respiratory failure admitted to the intensive care unit (ICU), 37 patients received HFNCO as initial therapy, and 26 patients were primarily treated with NIV. There was no significant difference between the 2 groups in terms of baseline characteristics, laboratory tests, arterial blood gases, PaO2/FiO2 values, and vital signs. Re-assessment after 24 h of starting treatment with either HFNCO or NIV showed significant improvement (PP>0.05) between the 2 groups as regards the duration of treatment, rate of endotracheal intubation with invasive mechanical ventilation, and mortality rate. Conclusion High flow nasal cannula oxygen (HFNCO) is effective in the management of acute hypoxemic respiratory failure associated with COVID-19. Its efficacy is similar to NIV, with no difference in the duration of treatment, endotracheal intubation rate, or mortality rate. |
| اللغة: | English |
| تدمد: | 2314-8551 1687-8426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ba99e4b9c5672c6012ce331ae12c39Test http://europepmc.org/articles/PMC7983081Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e5ba99e4b9c5672c6012ce331ae12c39 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23148551 16878426 |
|---|